These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. Loke YK; Singh S; Furberg CD CMAJ; 2009 Jan; 180(1):32-9. PubMed ID: 19073651 [TBL] [Abstract][Full Text] [Related]
5. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Yaturu S; Bryant B; Jain SK Diabetes Care; 2007 Jun; 30(6):1574-6. PubMed ID: 17363747 [No Abstract] [Full Text] [Related]
6. Type 2 diabetes, thiazolidinediones: bad to the bone? Watts NB; D'Alessio DA J Clin Endocrinol Metab; 2006 Sep; 91(9):3276-8. PubMed ID: 16960122 [No Abstract] [Full Text] [Related]
7. Distal upper and lower limb fractures associated with thiazolidinedione use. Jones SG; Momin SR; Good MW; Shea TK; Patric K Am J Manag Care; 2009 Aug; 15(8):491-6. PubMed ID: 19670952 [TBL] [Abstract][Full Text] [Related]
8. [Thiazolidinediones and skeletal health]. Meier C; Bodmer M; Meier CR; Kraenzlin ME Rev Med Suisse; 2009 Jun; 5(207):1309-10, 1312-3. PubMed ID: 19626930 [TBL] [Abstract][Full Text] [Related]
9. Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance? Schwartz AV; Sellmeyer DE Diabetes Care; 2007 Jun; 30(6):1670-1. PubMed ID: 17526825 [No Abstract] [Full Text] [Related]
10. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Aubert RE; Herrera V; Chen W; Haffner SM; Pendergrass M Diabetes Obes Metab; 2010 Aug; 12(8):716-21. PubMed ID: 20590749 [TBL] [Abstract][Full Text] [Related]
11. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. Douglas IJ; Evans SJ; Pocock S; Smeeth L PLoS Med; 2009 Sep; 6(9):e1000154. PubMed ID: 19787025 [TBL] [Abstract][Full Text] [Related]
13. Thiazolidinediones and fractures: evidence from translating research into action for diabetes. Bilik D; McEwen LN; Brown MB; Pomeroy NE; Kim C; Asao K; Crosson JC; Duru OK; Ferrara A; Hsiao VC; Karter AJ; Lee PG; Marrero DG; Selby JV; Subramanian U; Herman WH J Clin Endocrinol Metab; 2010 Oct; 95(10):4560-5. PubMed ID: 20631021 [TBL] [Abstract][Full Text] [Related]
14. Diabetes drug pioglitazone (Actos): risk of fracture. Meymeh RH; Wooltorton E CMAJ; 2007 Sep; 177(7):723-4. PubMed ID: 17823139 [No Abstract] [Full Text] [Related]
15. Fracture risk associated with common medications used in treating type 2 diabetes mellitus. Wolverton D; Blair MM Am J Health Syst Pharm; 2017 Aug; 74(15):1143-1151. PubMed ID: 28743778 [TBL] [Abstract][Full Text] [Related]
16. Study confirms link between certain diabetes drugs and fractures. Harv Womens Health Watch; 2010 May; 17(9):6. PubMed ID: 20593558 [No Abstract] [Full Text] [Related]
17. The safety of rosiglitazone in the treatment of type 2 diabetes. Singh S; Loke YK Expert Opin Drug Saf; 2008 Sep; 7(5):579-85. PubMed ID: 18759710 [TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone and pioglitazone. Beware fractures. Dixit A; Pandey P BMJ; 2009 Sep; 339():b3957. PubMed ID: 19808816 [No Abstract] [Full Text] [Related]
19. Thiazolidinediones and fracture risk in patients with Type 2 diabetes. Betteridge DJ Diabet Med; 2011 Jul; 28(7):759-71. PubMed ID: 21672000 [TBL] [Abstract][Full Text] [Related]
20. Bone loss and fracture risk associated with thiazolidinedione therapy. Riche DM; King ST Pharmacotherapy; 2010 Jul; 30(7):716-27. PubMed ID: 20575635 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]